Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy-Reference-Cited by-同舟云学术

Evaluation of family history in individuals with heterozygous BRCA pathogenic variants diagnosed with breast or ovarian cancer in a single center in Italy

Published:2022-10-28 Issue:12 Volume:10 Page:
ISSN:2324-9269
Container-title:Molecular Genetics & Genomic Medicine
language:en
Short-container-title:Molec Gen & Gen Med

Author:

Negri Serena¹,De Ponti Elena²,Sina Federica Paola³,Sala Elena⁴,Dell'Oro Cristina¹,Roversi Gaia⁴,Lazzarin Sara¹,Delle Marchette Martina¹,Inzoli Alesssandra¹^ORCID,Toso Claudia⁵,Fumagalli Simona¹,Campanella Maria⁶,Kotsopoulos Joanne⁷⁸,Fruscio Robert¹³^ORCID

Affiliation:

1. Clinic of Obstetrics and Gynecology, Department of Medicine and Surgery University of Milan‐Bicocca Milan Italy

2. Department of Physical Medicine ASST Monza, San Gerardo Hospital Monza Italy

3. UOC Gynecologic Surgery ASST Monza, San Gerardo Hospital Monza Italy

4. UO Medical Genetics ASST Monza, San Gerardo Hospital Monza Italy

5. UOC Gestione Sanitaria delle Convenzioni ATS Brianza Lecco Italy

6. aBRCAdabra ONLUS Milan Italy

7. Women's College Research Institute Women's College Hospital Toronto Ontario Canada

8. Dalla Lana School of Public Health University of Toronto Toronto Ontario Canada

Publisher

Wiley

Subject

Genetics (clinical),Genetics,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mgg3.2071

Reference29 articles.

1. AIOM.https://www.aiom.it/wp‐content/uploads/2021/07/2021_Racc_testBRCA_predittivo‐preventivo.pdf

2. BRCAMutation Frequency and Patterns of Treatment Response inBRCAMutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group

3. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies

4. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial

5. Awareness and Utilization of BRCA1/2 Testing Among U.S. Primary Care Physicians